Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.47 |
| ▸ | ACE | P12821 | 3/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | GRN | P28799 | 2/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680172 | 0.92 | ACE2 (0.52) | ACE2ACECYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL7429450 | 0.91 | ACE2 (0.46) | ACE2ACECYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL7382601 | 0.91 | CYP11B1 (0.47) | ACE2ACECYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL7391523 | 0.91 | ACE2 (0.48) | ACE2ACECYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL7382791 | 0.89 | ACE2 (0.49) | ACE2ACECYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL3712513 | 0.89 | ACE2 (0.45) | ACE2ACECYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL1655466 | 0.88 | ACE2 (0.48) | ACE2ACECYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL3704209 | 0.88 | ACE2 (0.44) | ACE2ACECYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL3712455 | 0.88 | MAPT (0.47) | ACE2ACECYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL1658173 | 0.88 | CYP11B1 (0.50) | ACE2ACECYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010093804-A1 | ACE2 INHIBITORS FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICALS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| EP-2059234-A1 | METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT | Ore Pharmaceuticals Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008031014-A1 | METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT | ORE PHARMACEUTICALS INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2000066104-A9 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1183019-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000066104-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | disclosed |